Amicus Therapeutics Inc.

"Mr. Crowley became president and CEO of Amicus in January 2005, having served as a director since 2004. Previously he was founding president and CEO of Orexigen Therapeutics. Preceding Orexigen, Mr. Crowley was senior vice president at Genzyme Therapeutics, a position he assumed after overseeing the sale of Novazyme Pharmaceuticals to Genzyme in September 2001. Mr. Crowley was the founding president and CEO of Novazyme that was developing a novel treatment for Pompe disease. He previously served in several senior management roles with the Bristol-Myers Squibb Company (BMS), including director of the Executive Committee for the U.S. Medicines Group, director of Business Strategy for the U.S. Pharmaceuticals Group, and director of U.S. Area Marketing for the Neuroscience and Infectious Disease Division. Preceding his experience at BMS, Mr. Crowley worked as a business strategy consultant for Marakon Associates. Mr. Crowley began his professional career as a litigation associate in the Health Care Practice Group of the Indianapolis-based law firm of Bingham, Summers, Welsh & Spilman. Mr. Crowley is involved with several charitable and community organizations, including serving on the Board of Directors of St. Peter's University Health Care System. Mr. Crowley's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease - a fatal neuromuscular disorder. Mr. Crowley and his family have been featured on the cover of The Wall Street Journal and on The Today Show, CNBC and The Paula Zahn Show on CNN. In 2006, Geeta Anand, Pulitzer prize winning writer for The Wall Street Journal, authored a book on Mr. Crowley entitled ""The Cure: How a Father Raised $100 Million- and Bucked the Medical Establishment- in a Quest to Save His Children."" (www.thecurebook.com). Mr. Crowley is a commissioned officer in the United States Navy Reserve (active). Mr. Crowley earned his B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, his J.D. from the University of Notre Dame Law School and his M.B.A. from Harvard Business School."

"Dr. David Lockhart joined Amicus Therapeutics in January 2006 as chief scientific officer. He brings to Amicus 13 years of industry experience and achievements including credit as the primary developer of genome-wide gene-expression profiling with high-density DNA arrays when he was at Affymetrix. Before coming to Amicus, Dr. Lockhart was president, CSO and co-founder of Ambit Biosciences in San Diego. He has served as director of genomics at the Genomics Institute of the Novartis Research Foundation, and he held various leadership positions during his more than five years at Affymetrix, including vice president of genomics research. Dr. Lockhart has also been a visiting scholar at the Salk Institute for Biological Studies. Dr. Lockhart received his Ph.D. in Chemistry from Stanford University and was a postdoctoral fellow at the Whitehead Institute at MIT under Professor Peter S. Kim. He has published nearly 60 peer-reviewed scientific articles on kinase technology, kinase inhibitor discovery, genomics and the use of genomic tools for important biological and biomedical problems."

"Mr. Dentzer joined Amicus in September 2006 as Chief Financial Officer. He joined the company from Biogen Idec Inc. where he served as Corporate Controller from November 2003 to September 2006. Prior to the November 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation, Mr. Dentzer served as Corporate Controller of Biogen, Inc. Prior to Biogen, he served in a variety of financial positions at E. I. du Pont de Nemours and Company, most recently as Chief Financial Officer of DuPont Flooring Systems. Mr. Dentzer received a B.A. from Boston College and an M.B.A. from the University of Chicago. "

Mr. Patterson joined Amicus in December 2004 and currently serves as Chief Operating Officer. Mr. Patterson was promoted to Chief Operating Officer from Chief Business Officer in September 2006. Prior to Amicus, Mr. Patterson served as vice president of Regulatory Affairs, and later vice president of Commercial Planning at BioMarin Pharmaceutical. Mr. Patterson oversaw the development of Aldurazyme® (laronidase) for the treatment of the genetic disease MPS I and helped build the sales and marketing function for the company. Prior to BioMarin, Mr. Patterson worked at Genzyme Corporation in Manufacturing and Regulatory Affairs. While at Genzyme he contributed to the development and global licensing of multiple products. Mr. Patterson received his B.A. in Biochemistry from Bowdoin College.

"Dr. Karin Ludwig joined Amicus Therapeutics in February 2006 and brings more than 15 years of medical experience to her position as senior vice president of Clinical Research. Dr. Ludwig began her industry career at Farmitalia Carlo Erba in her native Germany. In 1993 she became head of clinical research at Pharmacia in Erlangen, Germany, and held various positions in research and development at Pharmacia & Upjohn and Pharmacia in the U.S. and the U.K. through their acquisition by Pfizer in 2003. At Pfizer she held the position of group leader and senior director of endocrinology and ophthalmology for the U.S. medical program. Dr. Ludwig received her medical degree from Freiburg University and trained in general surgery at the University Hospital in Tuebingen, Germany."

Alex is a Managing Director of Prospect Venture Partners. Prior to co-founding Prospect Venture Partners I, II and III, Alex was a Partner at Kleiner Perkins Caufield & Byers (KPCB) from 1991 to 1997 where he focused on health care product company investments in the drug, device, and diagnostic sectors. Additionally, during his tenure at KPCB, Alex served as the founding CEO of two pioneering biotechnology companies, Geron (NASDAQ:GERN) and Connective Therapeutics, which became a Connetics, a NASDAQ listed specialty pharmaceutical company. For both of these companies, Alex worked with the scientific founders to develop the companies' initial business plans, in-license key enabling technology and products, recruit world class scientific talent and advisory board members, secure significant milestone-driven venture financing, and recruit experienced senior executive management teams. Prior to KPCB, Alex was a founder and CEO of BioBridge Associates, a health care industry consulting firm from 1989 to 1991. From 1987 to 1989, he served as the Director of Technology Development at Advanced Biosearch Associates, a regulatory affairs advisory firm where he focused on medical product commercialization and medical device regulatory strategy. Alex's research experience was gained at Memorial Sloan Kettering Cancer Center, the Genetics Department at the Toronto Hospital for Sick Children, the Whitehead Institute at MIT, and Duke University. Alex is currently Chairman of the Board of Geron (NASDAQ: GERN) and Tercica (NASDAQ: TRCA), and serves or has served on the Board of Directors of Amicus (NASDAQ: FOLD), Archemix, Connetics (now Stiefel Laboratories, Inc.), and of Complete Genomics, Inc., NeoMend, Novacept (now NASDAQ: CYTC), SurgRx, Transave, Verus Pharmaceuticals, Zelos Therapeutics and several other privately held companies. Alex received a Ph.D. in Biology from New York University and a B.A. in Biology from Brandeis University, where he currently is Chairman of the University Science Advisory Council and serves on the Board of Trustees.

"Dr. Palling brings more than 20 years of drug development experience to Amicus and has served as senior vice president of Drug Development since the company began operations in August 2002. He has responsibility for preclinical development and manufacturing. Previously, he was vice president of Worldwide Assay Research and Development at Ortho Clinical Diagnostics, a Johnson & Johnson Company, and prior to that he served as senior director of Pharmaceutical Development at Johnson & Johnson Pharmaceutical Research and Development. Prior to Johnson & Johnson, Dr. Palling worked at Hoffmann-La Roche where he held various management positions within Pharmaceutical Development. He was head of Analytical Research and Development, as well as an International Project Director leading multi-functional teams developing new medicines, primarily for oncology and virology. Dr. Palling received B.Sc. and Ph.D. degrees in Chemistry from the University of London, King's College, and conducted post-doctoral research in Biochemistry at Brandeis University."

"Dr. Licholai brings his experience in financing medical innovation, in clinical practice and in scientific research to his position overseeing Medical Affairs at Amicus. Prior to joining Amicus in 2004, he was a venture capitalist at Domain Associates, where he helped fund biotechnology and medical device start-up companies. Previously he was director of Ventures and Business Development for Medtronic Neurological, where he managed a global portfolio of novel drug delivery and neurological treatments for diseases such as Parkinson's disease, epilepsy, CNS malignancies and chronic pain syndromes. Dr. Licholai trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals. During his residency, Dr. Licholai also worked on hospital efficiency and merger strategies for Integral Consulting. He was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health. He did research in molecular genetics at Yale University and examined variants in hereditary blood diseases. Dr. Licholai also worked in molecular oncology at Rockefeller University. Additionally, while at Harvard Business School, he worked with Novartis and Millennium Pharmaceuticals. Dr. Licholai received his B.S. from Boston College and Pre-Medical studies at Columbia University, his M.D. from Yale Medical School and his M.B.A from Harvard Business School."

"Nicole Schaeffer has overseen Human Resources and Leadership Development at Amicus since March 2005. She brings over eight years of experience building talent at early stage biotechnology companies. Prior to joining Amicus, Ms. Schaeffer worked at Flagship Ventures helping to start several high-tech/biotech companies including Adnexus Therapeutics, Epitome Biosystems and BG Medicine. Ms. Schaeffer served as Director and later Senior Director of Human Resources for all three firms, responsible for all HR functions. Preceding her work with Flagship Ventures, Ms. Schaeffer rose from Manager to Director of Human Resources, responsible for all HR functions for Oak Industries, Inc., a publicly traded $450 million supplier of components to the communications industry. During her tenure, Oak Industries was acquired by Corning Inc. Ms. Schaeffer has also held a variety of human resources positions at EMC Corporation. Ms. Schaeffer received her B.A. from the University of Rochester and her M.B.A. from Boston University."

Greg is a graduate of Harvard College, Harvard Medical School and Harvard Business School, where he was a Baker Scholar. Prior to joining CHL Medical Partners in 2001, Greg was a Senior Associate at Whitney & Co. where he concentrated on private equity investments in healthcare technology and services companies. Prior to his graduate training, Greg was a financial analyst in the Healthcare Corporate Finance Group at Morgan Stanley & Co. where he worked on financings and merger and acquisition assignments for a number of biotechnology, pharmaceutical, and healthcare services clients. While at CHL, Greg has been the founding CEO of Amicus Therapeutics, Inc. where he has played a key role in identifying and licensing the platform technology, hiring the management team and developing the company's strategic plan. He also played a key role in the early development and financing of Fidelis SeniorCare, Inc., Resolvyx Pharmaceuticals, Inc. and VaxInnate Corporation. He currently serves as a director of these four companies.

P. Sherrill Neff has been a director since March 2005. Mr. Neff is a founder of Quaker BioVentures, Inc., a life sciences venture fund, and has been Managing Partner since 2002. He was a director of Resource America from 1998 to March 2005. From 1994 to 2002 he was President and Chief Financial Officer, and from 1994 to 2003, a director of Neose Technologies, Inc., a publicly-traded life sciences company. Mr. Neff was also a director of The Bancorp from its formation in 1999 until 2002.